We found no clear evidence that paroxetine was more or less effective compared with other antidepressants at increasing response to treatment at acute ( six to 12 weeks ) , early ( one to four weeks ) , or longer term follow-up ( four to six months ) .
Paroxetine was associated with a lower rate of adverse events than amitriptyline , imipramine and older ADs as a class , but was less well tolerated than agomelatine and hypericum .
Some possibly clinical ly meaningful differences between paroxetine and other ADs exist , but no definitive conclusions can be drawn from these findings .
In terms of early response to treatment ( one to four weeks ) there was moderate quality of evidence that mirtazapine was better than paroxetine and that paroxetine was better than reboxetine .
However there was no clear evidence that paroxetine was better or worse compared with other antidepressants at increasing response to treatment at any time point .
BACKGROUND Paroxetine is the most potent inhibitor of the reuptake of serotonin of all selective serotonin reuptake inhibitors ( SSRIs ) and has been studied in many r and omised controlled trials ( RCTs ) .
However , these comparative studies provided contrasting findings and systematic review s of RCTs have always considered the SSRIs as a group , and evidence applicable to this group of drugs might not be applicable to paroxetine alone .
The present systematic review assessed the efficacy and tolerability profile of paroxetine in comparison with tricyclics ( TCAs ) , SSRIs and newer or non-conventional agents .
OBJECTIVES 1 .
To determine the efficacy of paroxetine in comparison with other anti-depressive agents in alleviating the acute symptoms of Major Depressive Disorder.2  .
To review acceptability of treatment with paroxetine in comparison with other anti-depressive agents.3 .
To investigate the adverse effects of paroxetine in comparison with other anti-depressive agents .
What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors?
OBJECTIVE Although adverse events are a key factor in compliance , their evolution during treatment with antidepressants is poorly documented . Therefore , the time course of adverse events during 6 months of antidepressant treatment was investigated . METHOD 85 psychiatric out patients with a DSM-IV diagnosis of major depressive disorder ( with the exclusion of other DSM-IV Axis I disorders ) were enrolled between September 2002 and March 2003 in a multicenter , r and omized , double-blind trial with selective serotonin reup-take inhibitors ( fluoxetine [ N = 42 ] and paroxetine [ N = 43 ] ) . At each visit , the presence and severity of treatment-emergent adverse events were assessed systematic ally using the UKU Side Effect Rating Scale ( UKU ) . General linear mixed modeling was used to investigate the predictors of the time course of adverse events . RESULTS Overall , the number of at least moderately severe adverse events decreased with time . More severely depressed patients reported overall more ( at least moderately severe ) adverse events than less severely depressed patients ( p = .0002 ) , but the decrease in reported adverse events was comparable over time . Men ( N = 30 ) and women ( N = 55 ) reported initially the same number of at least moderately severe adverse events , but the habituation was more rapid in men ( p < .0001 ) . Completers ( N = 58 ) and dropouts ( N = 27 ) did not differ initially , but completers ' habituation was more rapid ( p = .014 ) . The habituation of adverse events was also more rapid in recurrent than in first-episode patients but only in men ( p = .0025 ) . CONCLUSION The time course of adverse events varies with the severity of depression , sex , completer or dropout status , and recurrent versus first-episode depression
We found no clear evidence that paroxetine was more or less effective compared with other antidepressants at increasing response to treatment at acute ( six to 12 weeks ) , early ( one to four weeks ) , or longer term follow-up ( four to six months ) .
Paroxetine was associated with a lower rate of adverse events than amitriptyline , imipramine and older ADs as a class , but was less well tolerated than agomelatine and hypericum .
Some possibly clinical ly meaningful differences between paroxetine and other ADs exist , but no definitive conclusions can be drawn from these findings .
In terms of early response to treatment ( one to four weeks ) there was moderate quality of evidence that mirtazapine was better than paroxetine and that paroxetine was better than reboxetine .
However there was no clear evidence that paroxetine was better or worse compared with other antidepressants at increasing response to treatment at any time point .
BACKGROUND Paroxetine is the most potent inhibitor of the reuptake of serotonin of all selective serotonin reuptake inhibitors ( SSRIs ) and has been studied in many r and omised controlled trials ( RCTs ) .
However , these comparative studies provided contrasting findings and systematic review s of RCTs have always considered the SSRIs as a group , and evidence applicable to this group of drugs might not be applicable to paroxetine alone .
The present systematic review assessed the efficacy and tolerability profile of paroxetine in comparison with tricyclics ( TCAs ) , SSRIs and newer or non-conventional agents .
OBJECTIVES 1 .
To determine the efficacy of paroxetine in comparison with other anti-depressive agents in alleviating the acute symptoms of Major Depressive Disorder.2  .
To review acceptability of treatment with paroxetine in comparison with other anti-depressive agents.3 .
To investigate the adverse effects of paroxetine in comparison with other anti-depressive agents .